Posted by Michael Wonder on 08 Aug 2016
Decision relating to enoxaparin sodium and plerixafor
8 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Sanofi-Aventis New Zealand Limited (Sanofi) for the listing of plerixafor for use in DHB hospitals, along with price reductions for enoxaparin sodium.
The funding of plerixafor means that a new pharmaceutical used to mobilise stem cells for autologous stem cell transplants will be funded for use in DHB hospitals from 1 September 2016. Plerixafor increases the likelihood of a successful mobilisation, reducing the delay to transplant for certain presentations of multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
